Candidiasis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Injection, Ointment, Oral), By Drug Type (Polyene, Azole, Echinocandin, Other), By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis), By End-User (Hospitals and Clinics, Retail Pharmacies, Other), By Region and Competition, 2020-2030F
Market Overview
The Global Candidiasis Therapeutics Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 4.78 billion by 2030, registering a CAGR of 6.22% during the forecast period. Candidiasis, a fungal infection primarily caused by Candida species, remains a growing healthcare concern across all age groups. Manifesting in forms such as oral thrush, vaginal infections, esophageal candidiasis, and invasive candidiasis, it poses heightened risks for immunocompromised populations—including individuals with HIV/AIDS, cancer patients, and transplant recipients. The widespread and sometimes inappropriate use of antibiotics has further contributed to its rising prevalence. In response, the global therapeutics market is witnessing rising demand for effective antifungal treatments. With a diverse and expanding patient base, the need for innovative and targeted therapies continues to drive investment and advancements within the market.
Key Market Drivers
The Rising Incidence of Candidiasis
Candidiasis, primarily caused by Candida albicans and increasingly by drug-resistant species such as Candida auris, is on the rise globally. In 2024, the CDC reported more than 34,000 cases of candidemia in the United States alone, underscoring a significant year-over-year increase. The emergence of Candida auris, detected in over 40 countries, highlights the infection's expanding global impact. Key contributing factors include the widespread use of antibiotics, which disrupt healthy microbial balance, and a growing population of immunocompromised individuals—such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. Aging demographics further heighten vulnerability to these infections. As the disease burden escalates, pharmaceutical and biotechnology companies are intensifying R&D efforts to develop advanced antifungal drugs. This momentum is reinforced by the need for therapeutics that are both more effective and capable of overcoming resistance, with many new treatments currently progressing through clinical trials.
Key Market Challenges
Antifungal Resistance
Antifungal resistance poses a major obstacle to candidiasis treatment worldwide. The increasing prevalence of multidrug-resistant strains, particularly Candida auris, has complicated the clinical landscape. In 2023 alone, over 2,400 cases of Candida auris were reported in the United States—nearly doubling from 2020 figures. Resistance to key antifungal classes such as azoles and echinocandins limits treatment options and increases reliance on less effective or more toxic alternatives. This trend is especially concerning in high-risk populations, including immunocompromised patients, where timely and successful intervention is crucial. The challenge underscores the need for continuous innovation and investment in resistance-mitigating therapies.
Key Market Trends
Antifungal Drug Development and Innovation
A leading trend in the Candidiasis Therapeutics Market is the sustained focus on novel antifungal drug development. The rise in drug-resistant infections has prompted pharmaceutical firms to prioritize research targeting resistant Candida species. Innovations include the development of next-generation antifungal agents as well as the exploration of combination therapies, which utilize multiple antifungal drugs to improve efficacy and reduce resistance risk. These advancements reflect a broader movement toward personalized, more effective treatment options, ensuring better outcomes for patients with complex or persistent infections.
Key Market Players
In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.
Available Customizations:
Global Candidiasis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The Global Candidiasis Therapeutics Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 4.78 billion by 2030, registering a CAGR of 6.22% during the forecast period. Candidiasis, a fungal infection primarily caused by Candida species, remains a growing healthcare concern across all age groups. Manifesting in forms such as oral thrush, vaginal infections, esophageal candidiasis, and invasive candidiasis, it poses heightened risks for immunocompromised populations—including individuals with HIV/AIDS, cancer patients, and transplant recipients. The widespread and sometimes inappropriate use of antibiotics has further contributed to its rising prevalence. In response, the global therapeutics market is witnessing rising demand for effective antifungal treatments. With a diverse and expanding patient base, the need for innovative and targeted therapies continues to drive investment and advancements within the market.
Key Market Drivers
The Rising Incidence of Candidiasis
Candidiasis, primarily caused by Candida albicans and increasingly by drug-resistant species such as Candida auris, is on the rise globally. In 2024, the CDC reported more than 34,000 cases of candidemia in the United States alone, underscoring a significant year-over-year increase. The emergence of Candida auris, detected in over 40 countries, highlights the infection's expanding global impact. Key contributing factors include the widespread use of antibiotics, which disrupt healthy microbial balance, and a growing population of immunocompromised individuals—such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. Aging demographics further heighten vulnerability to these infections. As the disease burden escalates, pharmaceutical and biotechnology companies are intensifying R&D efforts to develop advanced antifungal drugs. This momentum is reinforced by the need for therapeutics that are both more effective and capable of overcoming resistance, with many new treatments currently progressing through clinical trials.
Key Market Challenges
Antifungal Resistance
Antifungal resistance poses a major obstacle to candidiasis treatment worldwide. The increasing prevalence of multidrug-resistant strains, particularly Candida auris, has complicated the clinical landscape. In 2023 alone, over 2,400 cases of Candida auris were reported in the United States—nearly doubling from 2020 figures. Resistance to key antifungal classes such as azoles and echinocandins limits treatment options and increases reliance on less effective or more toxic alternatives. This trend is especially concerning in high-risk populations, including immunocompromised patients, where timely and successful intervention is crucial. The challenge underscores the need for continuous innovation and investment in resistance-mitigating therapies.
Key Market Trends
Antifungal Drug Development and Innovation
A leading trend in the Candidiasis Therapeutics Market is the sustained focus on novel antifungal drug development. The rise in drug-resistant infections has prompted pharmaceutical firms to prioritize research targeting resistant Candida species. Innovations include the development of next-generation antifungal agents as well as the exploration of combination therapies, which utilize multiple antifungal drugs to improve efficacy and reduce resistance risk. These advancements reflect a broader movement toward personalized, more effective treatment options, ensuring better outcomes for patients with complex or persistent infections.
Key Market Players
- Basilea Pharmaceutica Ltd
- Astellas Pharma Inc.
- SCYNEXIS, Inc.
- NovaDigm Therapeutics
- Mycovia Pharmaceuticals, Inc.
- Cidara Therapeutics Inc.
- Pfizer Inc.
- Bayer AG
- Viatris Inc.
- Novabiotics Limited
In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Candidiasis Therapeutics Market, By Route of Administration:
- Injection
- Ointment
- Oral
- Candidiasis Therapeutics Market, By Drug Type:
- Polyene
- Azole
- Echinocandin
- Other
- Candidiasis Therapeutics Market, By Anatomy Type:
- Oral Candidiasis
- Vulvovaginal Candidiasis
- Cutaneous Candidiasis
- Invasive Candidiasis
- Systemic Candidiasis
- Candidiasis Therapeutics Market, By End-User:
- Hospitals and Clinics
- Retail Pharmacies
- Other
- Candidiasis Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.
Available Customizations:
Global Candidiasis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Injection, Ointment, Oral)
5.2.2. By Drug Type (Polyene, Azole, Echinocandin, Other)
5.2.3. By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)
5.2.4. By End-User (Hospitals and Clinics, Retail Pharmacies, Other)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Drug Type
6.2.3. By Anatomy Type
6.2.4. By End-User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Candidiasis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Anatomy Type
6.3.1.2.4. By End-User
6.3.2. Canada Candidiasis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Anatomy Type
6.3.2.2.4. By End-User
6.3.3. Mexico Candidiasis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Anatomy Type
6.3.3.2.4. By End-User
7. EUROPE CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Drug Type
7.2.3. By Anatomy Type
7.2.4. By End-User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Candidiasis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Anatomy Type
7.3.1.2.4. By End-User
7.3.2. United Kingdom Candidiasis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Anatomy Type
7.3.2.2.4. By End-User
7.3.3. Italy Candidiasis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Anatomy Type
7.3.3.2.4. By End-User
7.3.4. France Candidiasis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Drug Type
7.3.4.2.3. By Anatomy Type
7.3.4.2.4. By End-User
7.3.5. Spain Candidiasis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Drug Type
7.3.5.2.3. By Anatomy Type
7.3.5.2.4. By End-User
8. ASIA-PACIFIC CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Drug Type
8.2.3. By Anatomy Type
8.2.4. By End-User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Candidiasis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Anatomy Type
8.3.1.2.4. By End-User
8.3.2. India Candidiasis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Anatomy Type
8.3.2.2.4. By End-User
8.3.3. Japan Candidiasis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Anatomy Type
8.3.3.2.4. By End-User
8.3.4. South Korea Candidiasis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Drug Type
8.3.4.2.3. By Anatomy Type
8.3.4.2.4. By End-User
8.3.5. Australia Candidiasis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Drug Type
8.3.5.2.3. By Anatomy Type
8.3.5.2.4. By End-User
9. SOUTH AMERICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Drug Type
9.2.3. By Anatomy Type
9.2.4. By End-User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Candidiasis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Anatomy Type
9.3.1.2.4. By End-User
9.3.2. Argentina Candidiasis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Anatomy Type
9.3.2.2.4. By End-User
9.3.3. Colombia Candidiasis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Anatomy Type
9.3.3.2.4. By End-User
10. MIDDLE EAST AND AFRICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Drug Type
10.2.3. By Anatomy Type
10.2.4. By End-User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Candidiasis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Drug Type
10.3.1.2.3. By Anatomy Type
10.3.1.2.4. By End-User
10.3.2. Saudi Arabia Candidiasis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Drug Type
10.3.2.2.3. By Anatomy Type
10.3.2.2.4. By End-User
10.3.3. UAE Candidiasis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Drug Type
10.3.3.2.3. By Anatomy Type
10.3.3.2.4. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL CANDIDIASIS THERAPEUTICS MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Bruker Corporation
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Astellas Pharma Inc.
14.3. SCYNEXIS, Inc.
14.4. NovaDigm Therapeutics
14.5. Mycovia Pharmaceuticals, Inc.
14.6. Cidara Therapeutics Inc.
14.7. Pfizer Inc.
14.8. Bayer AG
14.9. Viatris Inc.
14.10 Novabiotics Limited
15. STRATEGIC RECOMMENDATIONS
16.ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Injection, Ointment, Oral)
5.2.2. By Drug Type (Polyene, Azole, Echinocandin, Other)
5.2.3. By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)
5.2.4. By End-User (Hospitals and Clinics, Retail Pharmacies, Other)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Drug Type
6.2.3. By Anatomy Type
6.2.4. By End-User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Candidiasis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Anatomy Type
6.3.1.2.4. By End-User
6.3.2. Canada Candidiasis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Anatomy Type
6.3.2.2.4. By End-User
6.3.3. Mexico Candidiasis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Anatomy Type
6.3.3.2.4. By End-User
7. EUROPE CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Drug Type
7.2.3. By Anatomy Type
7.2.4. By End-User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Candidiasis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Anatomy Type
7.3.1.2.4. By End-User
7.3.2. United Kingdom Candidiasis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Anatomy Type
7.3.2.2.4. By End-User
7.3.3. Italy Candidiasis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Anatomy Type
7.3.3.2.4. By End-User
7.3.4. France Candidiasis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Drug Type
7.3.4.2.3. By Anatomy Type
7.3.4.2.4. By End-User
7.3.5. Spain Candidiasis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Drug Type
7.3.5.2.3. By Anatomy Type
7.3.5.2.4. By End-User
8. ASIA-PACIFIC CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Drug Type
8.2.3. By Anatomy Type
8.2.4. By End-User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Candidiasis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Anatomy Type
8.3.1.2.4. By End-User
8.3.2. India Candidiasis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Anatomy Type
8.3.2.2.4. By End-User
8.3.3. Japan Candidiasis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Anatomy Type
8.3.3.2.4. By End-User
8.3.4. South Korea Candidiasis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Drug Type
8.3.4.2.3. By Anatomy Type
8.3.4.2.4. By End-User
8.3.5. Australia Candidiasis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Drug Type
8.3.5.2.3. By Anatomy Type
8.3.5.2.4. By End-User
9. SOUTH AMERICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Drug Type
9.2.3. By Anatomy Type
9.2.4. By End-User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Candidiasis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Anatomy Type
9.3.1.2.4. By End-User
9.3.2. Argentina Candidiasis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Anatomy Type
9.3.2.2.4. By End-User
9.3.3. Colombia Candidiasis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Anatomy Type
9.3.3.2.4. By End-User
10. MIDDLE EAST AND AFRICA CANDIDIASIS THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Drug Type
10.2.3. By Anatomy Type
10.2.4. By End-User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Candidiasis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Drug Type
10.3.1.2.3. By Anatomy Type
10.3.1.2.4. By End-User
10.3.2. Saudi Arabia Candidiasis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Drug Type
10.3.2.2.3. By Anatomy Type
10.3.2.2.4. By End-User
10.3.3. UAE Candidiasis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Drug Type
10.3.3.2.3. By Anatomy Type
10.3.3.2.4. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. GLOBAL CANDIDIASIS THERAPEUTICS MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Bruker Corporation
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Astellas Pharma Inc.
14.3. SCYNEXIS, Inc.
14.4. NovaDigm Therapeutics
14.5. Mycovia Pharmaceuticals, Inc.
14.6. Cidara Therapeutics Inc.
14.7. Pfizer Inc.
14.8. Bayer AG
14.9. Viatris Inc.
14.10 Novabiotics Limited
15. STRATEGIC RECOMMENDATIONS
16.ABOUT US & DISCLAIMER
